Novel agent reduces new ossification lesions in patients with rare bone disease

CHICAGO — In patients with fibrodysplasia ossificans progressiva, an oral selective inhibitor of activin receptor–like kinase 2 was linked to lower odds of new heterotopic ossification lesions vs. placebo at 24 weeks, researchers reported. Interim results of the PROGRESS study, presented at ENDO 2026, included data from 63 patients aged 12 years or older with fibrodysplasia ossificans